Abstract
Osteoprotegerin (OPG) is a member of the tumour necrosis factor receptor superfamily of cytokines which, in spite of being initially described as a strong anti-resorptive factor, has lately been considered as a possible link between bone and vascular disease. In the last few years, several studies have evidenced its close relationship with the development of diabetes. In this review, we analyse the role of OPG in diabetic patients and its links with the most relevant associated diseases such as atherosclerosis, hypertension, endothelial dysfunction and diabetic nephropathy, as well as its connection with related pathologies as fibrosis, obesity and metabolic syndrome.
Keywords: Osteoprotegerin, diabetes, metabolic syndrome, fibrosis, blood pressure, endothelial dysfunction, atherosclerosis, nephropathy, cardiovascular disease, angiopathy, anti-resorptive factor, bone remodelling, RANKL, Src pathways, bone resorption
Current Molecular Medicine
Title: Osteoprotegerin and Diabetes-Associated Pathologies
Volume: 11 Issue: 5
Author(s): A. M. Blazquez-Medela, J. M. Lopez-Novoa and C. Martinez-Salgado
Affiliation:
Keywords: Osteoprotegerin, diabetes, metabolic syndrome, fibrosis, blood pressure, endothelial dysfunction, atherosclerosis, nephropathy, cardiovascular disease, angiopathy, anti-resorptive factor, bone remodelling, RANKL, Src pathways, bone resorption
Abstract: Osteoprotegerin (OPG) is a member of the tumour necrosis factor receptor superfamily of cytokines which, in spite of being initially described as a strong anti-resorptive factor, has lately been considered as a possible link between bone and vascular disease. In the last few years, several studies have evidenced its close relationship with the development of diabetes. In this review, we analyse the role of OPG in diabetic patients and its links with the most relevant associated diseases such as atherosclerosis, hypertension, endothelial dysfunction and diabetic nephropathy, as well as its connection with related pathologies as fibrosis, obesity and metabolic syndrome.
Export Options
About this article
Cite this article as:
M. Blazquez-Medela A., M. Lopez-Novoa J. and Martinez-Salgado C., Osteoprotegerin and Diabetes-Associated Pathologies, Current Molecular Medicine 2011; 11 (5) . https://dx.doi.org/10.2174/156652411795976565
DOI https://dx.doi.org/10.2174/156652411795976565 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Genetics and Diabetic Retinopathy
Current Diabetes Reviews Type 1 Diabetes Mellitus - Risk Factor for Cardiovascular Disease Morbidity and Mortality
Current Diabetes Reviews Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation
Mini-Reviews in Medicinal Chemistry Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease
Current Signal Transduction Therapy Kidney Injury Molcule-1 in Acute and Chronic Kidney Disease
Recent Patents on Biomarkers Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Vitamin D Metabolism and Potential Effects of Vitamin D Receptor Modulation in Chronic Kidney Disease
Current Drug Metabolism Fabry Disease Cardiomyopathy: from Genes to Clinical Manifestations
Current Pharmaceutical Biotechnology Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Uric Acid and Diabetes: Is there a Link?
Current Pharmaceutical Design Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design Antiplatelet Treatment in Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Inhibitors and Breakers of Advanced Glycation Endproducts (AGEs): A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Nitric Oxide Synthase and Cyclooxygenase Pathways: A Complex Interplay in Cellular Signaling
Current Medicinal Chemistry Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
Current Pharmaceutical Design Metabolic and Appetite Effects of Fructose and Glucose in Subjects with Type 1 Diabetes: A Randomized Crossover Clinical Trial
Current Diabetes Reviews PDE4D Gene in the STRK1 Region on 5q12: Susceptibility Gene for Ischemic Stroke
Current Medicinal Chemistry Therapeutic Potential of Resveratrol in Diabetic Nephropathy According to Molecular Signaling
Current Molecular Pharmacology